Extracellular Vesicles and Their Role in Patients With Multiple Myeloma
Avatar

Biologically Based Therapies for MM: Surveying Novel Options

By Extracellular Vesicles and Their Role in Patients With Multiple Myeloma FEATURING Kenneth Anderson
August 3, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

28:15
Bristol Myers Squibb Hematology

Considerations for Continuous Therapy in Multiple Myeloma

Feat. D. Landau

Featured Video

27:54
Bristol Myers Squibb Hematology

Importance of Maintenance Therapy in MM Patients Post Auto-HSCT

Feat. B. Randolph

Related Content

AUTOPLAY
06:50
ecancer

EHA 2021 Highlights on KRd for Lenalidomide-Refractory MM

Feat. C. Cerchione
15:57
SOHO 3rd Italian Conference

SOHO Italy 2021 on CAR T in MM: Preliminary Data and Perspectives

Feat. C. Cerchione
15:24
SOHO 3rd Italian Conference

SOHO Italy 2021 on R/R MM Treatment in Europe

Feat. C. Cerchione
19:13
SOHO Italy 1st School of Multiple Myeloma

Daratumumab in MM Daily Practice: Is It Becoming the New Backbone?

Feat. C. Cerchione
16:57
SOHO Italy 1st School of Multiple Myeloma

Anti-CD38 in MM Daily Practice: How Can We Potentiate the Action of …

Feat. C. Cerchione
34:28
2022 Community Oncology Conference

Treatment Conundrums in Myeloma

Feat. S. Giralt
04:29
ecancer

EHA 2022 on a Phase III GMMG-HD7 Trial: Isa-RVd as Induction Therapy…

Feat. E. Mai
23:18
Oncology Data Advisor

Can Diet and Nutrition Impact Multiple Myeloma Outcomes?

Feat. U. Shah, R. Banerjee
10:40
Claudio Cerchione

Frontline MM State of the Art: Can We Prolong PFS With D-VTd in ASCT…

26:05
SOHO Italy 1st School of Multiple Myeloma

Introducing Anti-CD38 in Daily Practice of MM: Updates on the GRIFFI…

Feat. C. Cerchione
17:29
SOHO Italy 1st Clinical and Biological School of CAR-T

How to Integrate CAR-T in the Clinical Scenario of Multiple Myeloma

Feat. C. Cerchione
01:29
ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on the Addition of Carfilzomib as a Thir…

Feat. C. Cerchione
31:36
Nebraska Oncology Society

ASCO 2022 on Moving Toward a Cure in Myeloma: The Role of MRD Testing

Feat. A. Nooka
14:06
UAB Hematology Review 2021

Frontline Daratumumab in MM: D-VTd vs. VTd, D-RVd vs. RVd in Transpl…

Feat. S. Bal
17:47
SOHO 3rd Italian Conference

SOHO Italy 2021 on MM: State of the Art Therapy in Europe

Feat. C. Cerchione
15:14
EHA 2022 Conference Coverage

How I Manage Frontline Multiple Myeloma

Feat. C. Cerchione
33:28
Cleveland Clinic Taussig Cancer Institute

Management of Relapsed/Refractory Multiple Myeloma

Feat. F. Anwer
17:59
Parameswaran Hari

Delivering the Best Initial Treatment for Myeloma: Induction Therapy…

04:26
ASCO 2022 Conference Coverage

2022 ASCO Annual Meeting "The Effects of AVM0703 Mobilization o…

Feat. J. Dalpez
36:30
Bristol Myers Squibb Hematology

A Physician Perspective on Treating NSCT NDMM

Feat. F. Davies